Literature DB >> 19691778

Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population.

Kazumasa Miki1, Mitsuhiro Fujishiro, Shinya Kodashima, Naohisa Yahagi.   

Abstract

BACKGROUND AND AIM: In order to reduce gastric cancer death, mass screening for gastric cancer has been established in Japan for several decades. Only photofluorography is considered to be an acceptable screening method so far, but recent evidence may show the usefulness of serum pepsinogen (PG) measurement for gastric cancer screening. The aim of the present study was to elucidate the feasibility of measuring serum PG levels for detection of gastric cancers.
METHODS: Serum PG levels (PGI/PGII) were measured in asymptomatic middle-aged Japanese between 1991 and 2005. Those with a PGI <or= 70 ng/mL and PGI/PGII <or= 3 were defined as having a positive PG test. According to the obtained results of serum PG levels and previous individual records, those with a positive PG test and those with a negative PG test took gastroendoscopy every 2 and 5 years, respectively.
RESULTS: The total number of participating individuals was 101,892 (mean age of 48.7 years). In a total of 21,178 planned gastroendoscopies (20.8%), 13,789 (65.1%) underwent gastroendoscopy and 125 gastric cancers were detected, which corresponded to 0.12% of all participants and to 0.91% of those with gastroendoscopy. Early-stage cancers and intestinal-type intramucosal cancers accounted for 80% and 39% of all the detected cancers, respectively.
CONCLUSIONS: Serum PG measurement for mass screening of gastric cancer enabled us to achieve high recruitment for gastroendoscopy in intended individuals, a favorable detection rate of gastric cancer and, in particular, an extremely high proportion of early-stage gastric cancer in all the detected cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19691778     DOI: 10.1111/j.1443-1661.2009.00839.x

Source DB:  PubMed          Journal:  Dig Endosc        ISSN: 0915-5635            Impact factor:   7.559


  32 in total

1.  Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus.

Authors:  Tan Han Loong; Ngiu Chai Soon; Nik Ritza Kosai Nik Mahmud; Jeevinesh Naidu; Rafiz Abdul Rani; Nazefah Abdul Hamid; Marjanu Hikmah Elias; Isa Mohamed Rose; Azmi Tamil; Norfilza M Mokhtar; Raja Affendi Raja Ali
Journal:  Biomed Rep       Date:  2017-09-20

2.  Endoscopy in screening for digestive cancer.

Authors:  René Lambert
Journal:  World J Gastrointest Endosc       Date:  2012-12-16

3.  Serum pepsinogens in gastric cancer screening.

Authors:  Pelayo Correa
Journal:  Dig Dis Sci       Date:  2010-08       Impact factor: 3.199

4.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

5.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

Review 6.  Biomarkers of Helicobacter pylori-associated gastric cancer.

Authors:  Cara L Cooke; Javier Torres; Jay V Solnick
Journal:  Gut Microbes       Date:  2013-07-12

7.  Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study.

Authors:  Daisuke Chinda; Tadashi Shimoyama; Tatsuya Mikami; Tetsu Arai; Daisuke Chiba; Yoshio Sasaki; Kazuo Komai; Yoshihiko Sawada; Yoshiharu Saito; Hironobu Chiba; Shinsaku Fukuda
Journal:  J Gastroenterol       Date:  2018-01-20       Impact factor: 7.527

8.  British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.

Authors:  Matthew Banks; David Graham; Marnix Jansen; Takuji Gotoda; Sergio Coda; Massimiliano di Pietro; Noriya Uedo; Pradeep Bhandari; D Mark Pritchard; Ernst J Kuipers; Manuel Rodriguez-Justo; Marco R Novelli; Krish Ragunath; Neil Shepherd; Mario Dinis-Ribeiro
Journal:  Gut       Date:  2019-07-05       Impact factor: 23.059

9.  First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.

Authors:  Yoshimasa Saito; Hiroshi Serizawa; Yukako Kato; Masaru Nakano; Masahiko Nakamura; Hidetsugu Saito; Hidekazu Suzuki; Takanori Kanai
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

10.  The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology.

Authors:  Marcis Leja; Limas Kupcinskas; Konrads Funka; Agnese Sudraba; Laimas Jonaitis; Audrius Ivanauskas; Dainius Janciauskas; Gediminas Kiudelis; Han-Mo Chiu; Jaw-Town Lin
Journal:  Dig Dis Sci       Date:  2009-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.